Pharmaceutical compounds targeted by MIF affinity-tethered moieties
US9549988B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jun 8, 2014 |
| Grant date | Jan 24, 2017 |
| Priority date | — |
| Expiry date | Nov 5, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC09B57/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed a compound, a pharmaceutical composition and a method of treatment using a pharmaceutical composition comprising a tethering moiety that is capable of binding to a macrophage migration inhibitory factor (MIF) polypeptide, optionally linked to a linker moiety and further covalently bound to a drug moiety or imaging agent. More specifically, there is disclosed a genus of affinity-tethering moieties covalently bound to a drug moiety or imaging agent either directly or optionally via a linker moiety to covalently link the tethering moiety to a drug moiety. Without being bound by theory, the disclosed pharmaceutical compounds are targeted to cancer cells or immune cells via an affinity-tethering moiety that hitch-hikes to or into its target cell while bound to endogenous MIF.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.